Adipotide results: what to expect and when
A fat-blood-vessel targeting peptide with monkey weight-loss data and kidney toxicity.
Also called: FTPP, FTTP, Prohibitin-TP01, Prohibitin-targeting peptide 1, CKGGRAKDC-GG-D(KLAKLAK)2.
Fat-loss peptides · Prohibitin-targeted proapoptotic peptidomimetic.
One registered phase 1 trial enrolled four men; no results posted. Seven animal study entries cover five papers, with three separate monkey cohorts.
Key studies
- Terminated phase 1: four participants: Four enrolled; the trial ended in 2019 without public results. (source)
- White-fat targeting in mice: Targeting fat blood vessels reduced body fat in mice. (source)
- Reduced eating in obese rodents: Reduced eating explained most weight loss in these rodent experiments. (source)
- Monkey dose-finding: Weight fell as dose rose, alongside kidney changes. (source)
- Four-week monkey efficacy study: Fat and weight fell in monkeys; kidney safety remained a concern. (source)
- Kidney toxicity in lean monkeys: Kidney injury occurred even at doses used for monkey weight-loss experiments. (source)
Related to Adipotide
- AOD-9604: A growth-hormone fragment whose largest obesity trial failed to show meaningful weight loss.
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
- Retatrutide: An experimental weekly injection with phase 3 weight-loss results.
- Tesamorelin: A peptide approved for deep abdominal fat in adults with HIV lipodystrophy.
- SS-31 (elamipretide): A peptide approved for Barth syndrome muscle strength; benefit needs confirmation and broader energy benefits remain unproven.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Acute kidney injury (AKI), NHS · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Concerns regarding the public health risks associated with unapproved peptide products, Therapeutic Goods Administration and Chief Medical Officer · Therapeutic Goods Administration · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Anaphylaxis, NHS · NHS · 2023
- Drugs@FDA: FDA-Approved Drugs, US Food and Drug Administration
- Search criteria - Drug Product Database online query, Health Canada · Health Canada
- Union Register, European Commission
- Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases., Ashraf AR et al. · JAMA network open · 2024
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.